Direct answer:API (API) listings should first identify the actual manufacturing, packaging or labelling activities and corresponding subjects and check API’s own Drug Listing. Listing, NDC or DMF authorization references to customer formulations cannot directly substitute API manufacturers for listing information; Customer information needs should be identified by specific submission fields and task-by-task.
I. Which API subjects need attention to registration and listing?
The API import description of FDA requires the registration of the applicable offshore manufacturing, repackaging, relabelling and recycling facilities and the listing of medicines (including API) for commercial distribution. The listing provided at the time of import should be in the manufacturer’s API and cannot be replaced by a customer formulation record.
The mere trade or coordination role cannot automatically be attributed to the same obligations as the actual manufacturing facility. Manufacturers, packaging and labelling facilities, exporters, importers and customer formulation enterprises should be cleared to check the actual activities and records of the parties.
II. How does Labeler Code, NDC and Drug Listing connect?
Labler Code, used to identify relevant companies, is an integral part of the NDC; The existing code and the application application application and confirmation process should be verified before the first listing. It is not required to reapply a generic facility number for each production site, nor is it a product approval.
Drug Listing submits information on specific medicines and applicable labelling, packaging, composition and manufacturing facilities. The appropriate SPL file type should be selected and product properties such as bulk indient checked, and the content of the finished list cannot be moved to API without judgement.
For basic concepts and specific services seeDrug Listing and NDC GuideandLabeler Code, NDC and Drug Listing Service。
3. Is it necessary to have all the information on the client of the formulation?
It is not possible to summarize all API projects into a set of documents that must be made available to the formulation client. This time, it should be stated whether API has its own listing, requests for support for the customer formulation, or a DMF authorized reference, and then the field-by-field confirmation, the purpose and the basis for the submission.
API Listing requires checking information on its products, labels, related facilities and activities; The applicable incomplete drug information may also involve information such as DMF numbers already available. If customer applications, customer listings or LOAs are processed simultaneously, the customer information is supplemented by the corresponding association and authorization requirements.
In the event of an unclear request for information, it is recommended that the information be identified for which submission, who will provide and sign it, and whether the necessary information can be provided in an applicable manner; API listings and customer formulations should not be mixed.
IV. What information should be prepared in advance of the recommendation?
- API name, use, product properties, composition or strength information and applicable labels.
- Name, identification information and activities of the facility in question, such as actual manufacture, packaging labelling, etc.
- The company has a record of Labeler Code, NDC, facility registration and listing.
- Appropriate product packaging, labelling and SPL submission and FDA feedback are available.
- There are DMF numbers and applications to be supported, LOAs or client collaboration matters (if applicable).
- Import chains, internal officers, changes and annual maintenance arrangements.
The information should be checked against products and activities and not replace product-level information with a general corporate profile. Detailed confidential information is provided upon confirmation of use, authorization and handover arrangements.
V. API Lists and DMFs, respectively, what are the issues addressed?
The DMF is used to submit confidential technical content that can be cited as authorized, and the relevant technical information is usually reviewed in conjunction with the reference application. API Lists record the applicable information on drugs, labels and manufacturing activities. The two tasks may be relevant, but they are not the same submission and will not be done automatically with each other.
For technical documents to be created or maintained at the same time, reference may be made toDMF and eCTD GuideandDrug Master File (DMF) ServicesConfirmation of listings, technical papers and references to authorizations, and quotations.
VI. How are updates, queries and costs reconciled?
The FDA requires that the listings be updated as required and that the annual accreditation arrangements be reconciled if they remain unchanged. Changes in the information on new products, labels or facilities should be recorded in the corresponding submission, feedback and version, and should not be considered as always valid on the sole basis of the numbering.
Query checks database uses, current coverage, product status and search conditions. The current NDC Directory page of the FDA explains that it contains listing information for finished products and incomplete medicines, with conditions for publication such as valid status and listing certification; The listing certification here does not imply the approval of the FDA product. It would not be appropriate to use the catalogue scope expression in the old material as a direct rule. Where records are not found, further checks should be made between the submission status and the scope of application to be made public.
The submission of generic listings is a different matter from the applicable user fees, and the specific costs and preparation cycles are checked against the activities of the enterprise, the information, the scope of maintenance and current requirements. The cost of services should be stated separately from official costs.
VII. FACTUAL ISSUES
Customers are listed. API manufacturers need their own records?API’s own applicable obligations should be checked and cannot rely solely on customer formulation listing; The FDA import instructions explicitly require the API listing of the manufacturer.
Is there a DMF that doesn't have to deal with listing?This cannot be inferred. DDFs, listings and facility registrations should be judged separately.
Does a company need new facilities, Labeler Code?The existing code should be checked against the actual subject relationship, and the FDA indicates that several facilities of the same manufacturer can use a Labeler Code.
VIII. Official sources and entry points
- FDA | API Import and listing requirements
- FDA | Drug Listing Fields, Submit and Update
- FDA | Labeler Code Request and Confirmation
- eCFR | 21 CFR 207.49: manufacturer listing information
- FDA's current NDC Directory Scope & Description
The list of information and the scope of the commission is determined by providing a list of business roles, API categories and records that confirm whether this is a code, listing, maintenance or DMF-related exercise.
Look at the drug listing service and scope of application.
Submission of API listing requirements, communication information and quotations
Official data checks and updates: 2026-11-06. Author: Mr. Otsun; Audit: Mr. Toto. This paper focuses on the application of API for human use, and specific obligations and information requirements depend on the activities of the enterprise, its products and existing rules.
Continue reading and preparation
Further consolidation of project information is availableNDC Labeler Code Application, NDC Encoding and Drug Listing; The scope, processing cycles and costs are shown on the corresponding service page.